Hospital
Kaiser Foundation Hospitals
Kaiser Foundation Hospitals was paid $128.11M by Medicaid between Jan 2018 and Dec 2024, across 353 billing codes. Its largest line is 99284, emergency room visit (serious) — 21% of everything it billed.
33Billing provider infoKAISER FOUNDATION HOSPITALS
SACRAMENTO, CA 95823
SACRAMENTO, CA 95823
33aNPI1528138088assigned 11/09/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$128.11M
24GClaims2,700,377
24DCodes billed353
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#13 of 410
Median peer was paid$6.90M
This provider vs. median19×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 236,469 | $11.95M | |
| 2019 | 354,144 | $16.39M | |
| 2020 | 316,497 | $20.39M | |
| 2021 | 400,339 | $18.37M | |
| 2022 | 437,289 | $19.17M | |
| 2023 | 486,373 | $20.25M | |
| 2024incomplete | 469,266 | $21.59M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 21% | 38,706 | 35,670 | $26.89M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 17% | 46,240 | 43,837 | $21.99M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 8.1% | 39,698 | 38,101 | $10.42M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 7.1% | 13,768 | 12,616 | $9.14M |
| G0378 | Hospital observation service, per hour | 4.1% | 7,617 | 5,485 | $5.23M |
| 0450 | Emergency room services | 3.7% | 94,749 | 84,147 | $4.70M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.1% | 13,185 | 12,795 | $3.93M |
| 71046 | Radiologic examination, chest; 2 views | 1.8% | 36,750 | 35,569 | $2.27M |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.7% | 16,561 | 16,012 | $2.16M |
| 70450 | Computed tomography, head or brain; without contrast material | 1.6% | 17,693 | 16,885 | $2.01M |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 1.4% | 18,797 | 18,468 | $1.75M |
| 99199 | Unlisted special service, procedure or report | 1.3% | 33,060 | 28,428 | $1.71M |
341 more codes
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 1.2% | 1,425 | $1.50M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.0% | 6,960 | $1.34M |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 10,984 | $1.15M |
| 71045 | Radiologic examination, chest; single view | <1% | 25,708 | $1.12M |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 4,979 | $1.01M |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 8,696 | $977K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 13,374 | $866K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 133,768 | $687K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 2,597 | $656K |
| 76830 | Ultrasound, transvaginal | <1% | 5,752 | $656K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 5,806 | $648K |
| 99499 | <1% | 8,820 | $644K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 4,536 | $633K |
| 73630 | <1% | 8,759 | $576K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 47,369 | $575K |
| 73564 | <1% | 5,058 | $557K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 4,331 | $533K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 24,553 | $504K |
| 72100 | <1% | 4,642 | $497K | |
| 73610 | <1% | 6,887 | $470K | |
| 73030 | <1% | 7,128 | $460K | |
| 73130 | <1% | 7,071 | $449K | |
| 93971 | <1% | 3,980 | $440K | |
| 80051 | <1% | 95,988 | $429K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 16,442 | $429K |
| 36415 | Collection of venous blood by venipuncture | <1% | 126,070 | $420K |
| 73560 | <1% | 6,133 | $359K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 545 | $350K |
| 73110 | <1% | 5,029 | $323K | |
| 0270 | <1% | 27,178 | $314K | |
| 93970 | <1% | 1,814 | $312K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 15,654 | $310K |
| 83880 | <1% | 19,405 | $309K | |
| 82565 | <1% | 105,820 | $309K | |
| 86900 | <1% | 8,958 | $304K | |
| 59025 | Fetal non-stress test | <1% | 1,889 | $298K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 301 | $296K |
| 74018 | <1% | 4,083 | $293K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 19,417 | $287K |
| 70491 | <1% | 1,387 | $287K | |
| 70486 | <1% | 1,862 | $280K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 8,951 | $278K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 5,375 | $272K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,189 | $265K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,264 | $253K |
| 93976 | <1% | 1,245 | $245K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 7,693 | $235K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 7,693 | $234K |
| G0390 | Trauma response team associated with hospital critical care service | <1% | 246 | $234K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 586 | $230K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 14,987 | $227K |
| 82947 | <1% | 96,392 | $219K | |
| 84520 | <1% | 96,086 | $219K | |
| 73080 | <1% | 3,257 | $214K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 968 | $213K |
| 76642 | <1% | 2,300 | $210K | |
| 73502 | <1% | 3,244 | $206K | |
| 76770 | <1% | 1,799 | $203K | |
| 84460 | <1% | 61,285 | $198K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 15,852 | $197K |
| 82247 | <1% | 61,384 | $196K | |
| 47562 | <1% | 40 | $196K | |
| 83690 | <1% | 46,196 | $195K | |
| 73140 | <1% | 2,848 | $192K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 9,238 | $191K |
| 84450 | <1% | 58,153 | $184K | |
| 84702 | <1% | 16,681 | $181K | |
| 73590 | <1% | 3,140 | $181K | |
| 88142 | <1% | 9,235 | $179K | |
| 81001 | <1% | 62,154 | $171K | |
| 77065 | Tomosynthesis, mammo | <1% | 1,375 | $170K |
| 84075 | <1% | 53,862 | $168K | |
| 84484 | <1% | 27,540 | $159K | |
| 77080 | <1% | 2,321 | $155K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 6,240 | $154K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 908 | $149K |
| 73090 | <1% | 2,599 | $141K | |
| 72040 | <1% | 1,895 | $139K | |
| 87631 | <1% | 3,101 | $134K | |
| 76870 | <1% | 1,305 | $131K | |
| 86850 | <1% | 7,441 | $130K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 11,140 | $129K |
| 70544 | <1% | 677 | $128K | |
| 74022 | <1% | 1,336 | $120K | |
| 88307 | <1% | 701 | $119K | |
| 76536 | <1% | 1,037 | $115K | |
| 86901 | <1% | 8,956 | $113K | |
| 71250 | <1% | 851 | $110K | |
| 88304 | <1% | 2,344 | $107K | |
| 0762 | <1% | 416 | $102K | |
| 83735 | <1% | 29,222 | $102K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 21,197 | $99K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 29,771 | $98K |
| J3490 | Unclassified drugs | <1% | 19,116 | $91K |
| 72170 | <1% | 1,261 | $90K | |
| 86923 | <1% | 935 | $88K | |
| 72070 | <1% | 799 | $86K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 5,845 | $83K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,927 | $82K |
| 80306 | <1% | 9,694 | $81K | |
| 72141 | <1% | 351 | $80K | |
| 71101 | <1% | 725 | $73K | |
| 76857 | <1% | 655 | $71K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 22,215 | $68K |
| 73660 | <1% | 994 | $68K | |
| 72082 | <1% | 443 | $66K | |
| 73552 | <1% | 1,028 | $63K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 20,246 | $62K |
| 77066 | Tomosynthesis, mammo | <1% | 376 | $61K |
| 73562 | <1% | 1,224 | $60K | |
| 73060 | <1% | 1,124 | $60K | |
| 70547 | <1% | 349 | $58K | |
| 73522 | <1% | 449 | $56K | |
| 88312 | <1% | 607 | $56K | |
| 83605 | <1% | 9,151 | $55K | |
| 87088 | <1% | 13,106 | $54K | |
| 81003 | <1% | 28,950 | $53K | |
| 87040 | <1% | 6,382 | $52K | |
| 82570 | <1% | 10,536 | $51K | |
| 82077 | <1% | 7,393 | $51K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 1,448 | $50K |
| 85610 | <1% | 21,075 | $50K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,169 | $48K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 20,247 | $48K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 726 | $46K |
| 85652 | <1% | 15,301 | $46K | |
| 96376 | <1% | 4,371 | $43K | |
| 76882 | <1% | 427 | $42K | |
| 0160 | <1% | 759 | $41K | |
| 84100 | <1% | 19,193 | $41K | |
| 82248 | <1% | 9,052 | $41K | |
| 85027 | <1% | 7,921 | $39K | |
| 0637 | <1% | 146,757 | $39K | |
| Z7502 | <1% | 2,135 | $39K | |
| 90715 | <1% | 1,099 | $35K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 549 | $35K |
| 84156 | <1% | 10,337 | $34K | |
| 82962 | <1% | 16,568 | $33K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 2,003 | $30K |
| 80179 | <1% | 4,246 | $30K | |
| 74183 | <1% | 68 | $30K | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 347 | $29K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 8,627 | $29K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 6,885 | $29K |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 377 | $29K |
| 10060 | <1% | 1,444 | $28K | |
| 44970 | <1% | 15 | $25K | |
| 72050 | <1% | 246 | $25K | |
| 82803 | <1% | 2,696 | $24K | |
| 84703 | <1% | 6,603 | $23K | |
| 78451 | <1% | 25 | $23K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 6,817 | $23K |
| 82310 | <1% | 5,902 | $22K | |
| 0710 | <1% | 4,429 | $22K | |
| 70496 | <1% | 95 | $21K | |
| 84132 | <1% | 6,530 | $21K | |
| 82040 | <1% | 5,200 | $20K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 6,291 | $19K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,294 | $19K |
| 87449 | <1% | 1,785 | $18K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 698 | $17K |
| 87324 | <1% | 1,740 | $17K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 4,700 | $17K |
| 86780 | <1% | 1,794 | $16K | |
| 84295 | <1% | 4,353 | $16K | |
| 86140 | <1% | 4,612 | $15K | |
| 93923 | <1% | 82 | $15K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 5,273 | $15K |
| 85379 | <1% | 2,476 | $15K | |
| 87210 | <1% | 3,417 | $14K | |
| 74019 | <1% | 243 | $14K | |
| 12011 | <1% | 909 | $14K | |
| 12001 | <1% | 1,255 | $14K | |
| J1815 | Injection, insulin, per 5 units | <1% | 7,291 | $13K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 3,728 | $13K |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 5,043 | $13K |
| 85730 | <1% | 2,251 | $13K | |
| 70498 | <1% | 73 | $13K | |
| 27502 | <1% | 20 | $13K | |
| 85378 | <1% | 2,362 | $13K | |
| 93458 | <1% | 14 | $13K | |
| 74178 | <1% | 38 | $13K | |
| 72131 | <1% | 107 | $12K | |
| 83615 | <1% | 2,011 | $12K | |
| 0370 | <1% | 3,816 | $12K | |
| 12002 | <1% | 603 | $11K | |
| 82140 | <1% | 1,396 | $11K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 31 | $10K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 259 | $9K |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,769 | $9K |
| 72220 | <1% | 108 | $9K | |
| 0250 | <1% | 36,598 | $9K | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 3,428 | $9K |
| 82550 | <1% | 2,059 | $9K | |
| 97161 | <1% | 1,107 | $9K | |
| 73000 | <1% | 147 | $9K | |
| 96367 | <1% | 836 | $8K | |
| 29125 | <1% | 1,009 | $8K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 914 | $8K |
| 72197 | <1% | 12 | $8K | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 772 | $8K |
| 76801 | <1% | 78 | $8K | |
| 84550 | <1% | 2,146 | $8K | |
| J8501 | Aprepitant, oral, 5 mg | <1% | 1,167 | $7K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,720 | $7K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 75 | $7K |
| 70460 | <1% | 46 | $7K | |
| C1769 | Guide wire | <1% | 1,073 | $7K |
| 77061 | <1% | 42 | $6K | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 273 | $6K |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 2,167 | $6K |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 25 | $6K |
| 0121 | <1% | 12 | $6K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,273 | $5K |
| 76000 | <1% | 287 | $5K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 473 | $5K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,830 | $5K |
| 77062 | <1% | 26 | $5K | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 2,230 | $5K |
| 87081 | <1% | 1,692 | $5K | |
| 0301 | <1% | 26 | $4K | |
| 73620 | <1% | 111 | $4K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,422 | $4K |
| 75574 | <1% | 13 | $4K | |
| 87070 | <1% | 1,062 | $4K | |
| 80047 | <1% | 610 | $4K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 2,574 | $4K |
| 73700 | <1% | 24 | $4K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 910 | $4K |
| 82272 | <1% | 794 | $4K | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 794 | $4K |
| 87205 | <1% | 1,288 | $3K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,050 | $3K |
| 89051 | <1% | 827 | $3K | |
| 73120 | <1% | 35 | $3K | |
| 85014 | <1% | 2,353 | $3K | |
| 88342 | <1% | 47 | $3K | |
| 80349 | <1% | 3,088 | $3K | |
| 90749 | <1% | 934 | $3K | |
| 85007 | <1% | 1,169 | $3K | |
| 70360 | <1% | 44 | $3K | |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | <1% | 886 | $3K |
| 88173 | <1% | 42 | $3K | |
| 73501 | <1% | 54 | $2K | |
| 80164 | <1% | 347 | $2K | |
| 87506 | <1% | 46 | $2K | |
| 29515 | <1% | 207 | $2K | |
| 80069 | <1% | 604 | $2K | |
| 73100 | <1% | 40 | $2K | |
| 94060 | <1% | 33 | $2K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,738 | $2K |
| 0320 | <1% | 89 | $2K | |
| 73600 | <1% | 42 | $2K | |
| 72072 | <1% | 15 | $2K | |
| 90686 | <1% | 110 | $2K | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 445 | $2K |
| 96368 | <1% | 318 | $2K | |
| 85008 | <1% | 1,146 | $1K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 19 | $1K |
| 82728 | <1% | 280 | $1K | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 222 | $1K |
| 88112 | <1% | 43 | $1K | |
| 85018 | <1% | 1,126 | $1K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 3,032 | $1K |
| 85013 | <1% | 324 | $1K | |
| 80061 | Lipid panel | <1% | 286 | $970.27 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 104 | $925.46 |
| T1999 | Miscellaneous therapeutic items and supplies, retail purchases, not otherwise classified; identify product in "remarks" | <1% | 75 | $885.08 |
| 82150 | <1% | 115 | $729.82 | |
| 85045 | <1% | 330 | $728.50 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 239 | $698.99 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 288 | $681.54 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 1,244 | $658.18 |
| 86803 | <1% | 67 | $454.74 | |
| 87340 | <1% | 68 | $453.78 | |
| 84439 | <1% | 81 | $440.45 | |
| 99070 | <1% | 48 | $439.93 | |
| 80325 | <1% | 1,849 | $431.63 | |
| 76942 | <1% | 71 | $389.45 | |
| 87529 | <1% | 13 | $373.12 | |
| 64400 | <1% | 26 | $372.05 | |
| 0258 | <1% | 1,746 | $369.24 | |
| 80320 | <1% | 1,365 | $358.16 | |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 135 | $357.29 |
| 0305 | <1% | 12 | $337.00 | |
| 88300 | <1% | 15 | $330.00 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 218 | $327.30 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 53 | $310.60 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 212 | $310.19 |
| 82435 | <1% | 88 | $287.00 | |
| 82374 | <1% | 72 | $252.00 | |
| 0636 | <1% | 284 | $248.36 | |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | <1% | 32 | $237.68 |
| 86703 | <1% | 48 | $226.26 | |
| 89055 | <1% | 77 | $226.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 58 | $197.90 |
| 29130 | <1% | 51 | $197.55 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 73 | $192.09 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 422 | $186.57 |
| 80178 | <1% | 43 | $175.34 | |
| 94660 | <1% | 25 | $173.22 | |
| J2280 | Injection, moxifloxacin, 100 mg | <1% | 213 | $170.00 |
| G0143 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with manual screening and rescreening by cytotechnologist under physician supervision | <1% | 90 | $167.04 |
| 92610 | <1% | 87 | $162.80 | |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 16 | $134.06 |
| 83930 | <1% | 66 | $132.47 | |
| 82607 | <1% | 25 | $123.10 | |
| 80329 | <1% | 864 | $105.78 | |
| 29105 | <1% | 25 | $103.83 | |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 17 | $95.04 |
| 80346 | <1% | 703 | $90.90 | |
| 76937 | <1% | 87 | $87.76 | |
| 86706 | <1% | 15 | $86.92 | |
| 83935 | <1% | 42 | $84.02 | |
| 84300 | <1% | 52 | $72.02 | |
| 84155 | <1% | 49 | $71.26 | |
| 83550 | <1% | 27 | $70.20 | |
| 86704 | <1% | 12 | $69.71 | |
| Z7610 | <1% | 100 | $63.57 | |
| 83540 | <1% | 27 | $54.89 | |
| J1920 | Injection, labetalol hydrochloride, 5 mg | <1% | 36 | $53.19 |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 46 | $50.41 |
| J0737 | Injection, clindamycin phosphate (baxter), not therapeutically equivalent to j0736, 300 mg | <1% | 32 | $41.91 |
| 36430 | <1% | 66 | $40.76 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 13 | $35.84 |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 84 | $34.30 |
| 80324 | <1% | 460 | $30.00 | |
| 80353 | <1% | 93 | $18.00 | |
| 80356 | <1% | 90 | $18.00 | |
| J0613 | Injection, calcium gluconate (wg critical care), not therapeutically equivalent to j0612, 10 mg | <1% | 13 | $16.94 |
| G0008 | Administration of influenza virus vaccine | <1% | 35 | $7.15 |
| V2632 | Posterior chamber intraocular lens | 0% | 229 | $0.00 |
| G9754 | A finding of an incidental pulmonary nodule | 0% | 15 | $0.00 |
| 0272 | 0% | 931 | $0.00 | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 285 | $0.00 |
| 76376 | 0% | 359 | $0.00 | |
| 80365 | 0% | 38 | $0.00 | |
| C1758 | Catheter, ureteral | 0% | 12 | $0.00 |
| 80361 | 0% | 39 | $0.00 | |
| J7510 | Prednisolone oral, per 5 mg | 0% | 29 | $0.00 |
| 76706 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRODRIGUEZ, PATRICIA (SENIOR VICE PRESIDENT, AREA MANAGER)
| Provider | Location | Paid |
|---|---|---|
| Patricia Rodriguez, FNP-C & Associates | San Luis, AZ | $2.83M |
| House of the Sacred Journey INC | Las Vegas, NM | $783K |
| Evolution Care Services LLC | Miami Lakes, FL | $440K |
| Rio Grande PHC Service LLC | Brownsville, TX | $253K |
| Evolution Care Services LLC | Hollywood, FL | $23K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.